Details of the Drug
General Information of Drug (ID: DMTN5XI)
Drug Name |
Chlordiazepoxide
|
|||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Synonyms |
Abboxide; Balance; Chloradiazepoxide; Chlordiazachel; Chlordiazepoxid; Chlordiazepoxidum; Chlordiazepoxydum; Chloridazepoxide; Chloridiazepide; Chloridiazepoxide; Chlorodiazepoxide; Chlozepid; Clopoxide; Clordiazepossido; Clordiazepoxido; Control; Decacil; Disarim; Eden; Elenium; Helogaphen; Ifibrium; Kalmocaps; Librelease; Librinin; Libritabs; Librium; Lygen; Menrium; Mesural; Methaminodiazepoxide; Mildmen; Multum; Napoton; Napton; Psicosan; Radepur; Risolid; Silibrin; Sonimen; Tropium; Viopsicol; Zeisin; Zetran; Chlordiazepoxide Base; Clordiazepossido [Italian]; A-Poxide; Apo-Chlordiazepoxide; Balance (pharmaceutical); Chlordiazepoxidum [INN-Latin]; Clordiazepoxido [INN-Spanish]; Eden-psich; Libritabs (TN); Librium (TN); MENRIUM 10-4; MENRIUM 5-4; Novapam (TN); Novo-Poxide; Tropium (TN); Chlordiazepoxide (JP15/USP/INN); Chlordiazepoxide [USAN:INN:BAN:JAN]; 3H-1,4-Benzodiazepin-2-amine, 7-chloro-N-methyl-5-phenyl, 4-oxide; 3H-1,4-Benzodiazepin-2-amine, 7-chloro-N-methyl-5-phenyl-, 4-oxide; 3H-1,4-Benzodiazepine, 7-chloro-2-(methylamino)-5-phenyl-, 4-oxide; 3H-1,4-benzodiazepin-2-amine,7-chloro-N-methyl-5-phenyl-,4-oxide; 7-Chlor-2-methylamino-5-phenyl-3H-1,4-benzodiazepin-4-oxid; 7-Chlor-2-methylamino-5-phenyl-3H-1,4-benzodiazepin-4-oxid [German]; 7-Chloro-2-(methylamino)-5-phenyl-3H-1,4-benzodiazepine 4-oxide; 7-Chloro-N-methyl-5-phenyl-3H-1,4-benzodiazepin-2-amine 4-oxide; 7-Cloro-2-metilamino-5-fenil-3H-1,4-benzodiazepina 4-ossido; 7-Cloro-2-metilamino-5-fenil-3H-1,4-benzodiazepina 4-ossido [Italian]; 7-chloro-4-hydroxy-N-methyl-5-phenyl-3H-1,4-benzodiazepin-2-imine
|
|||||||||||||||||||||||||||||||||||||||||||||||||||
Indication |
|
|||||||||||||||||||||||||||||||||||||||||||||||||||
Therapeutic Class |
Antianxiety Agents
|
|||||||||||||||||||||||||||||||||||||||||||||||||||
Drug Type |
Small molecular drug
|
|||||||||||||||||||||||||||||||||||||||||||||||||||
Structure | ||||||||||||||||||||||||||||||||||||||||||||||||||||
3D MOL | 2D MOL | |||||||||||||||||||||||||||||||||||||||||||||||||||
#Ro5 Violations (Lipinski): 0 | Molecular Weight (mw) | 299.75 | ||||||||||||||||||||||||||||||||||||||||||||||||||
Logarithm of the Partition Coefficient (xlogp) | 2.4 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Rotatable Bond Count (rotbonds) | 1 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Hydrogen Bond Donor Count (hbonddonor) | 1 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Hydrogen Bond Acceptor Count (hbondacc) | 3 | |||||||||||||||||||||||||||||||||||||||||||||||||||
ADMET Property |
|
|||||||||||||||||||||||||||||||||||||||||||||||||||
Chemical Identifiers |
|
|||||||||||||||||||||||||||||||||||||||||||||||||||
Cross-matching ID | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Repurposed Drugs (RPD) | Click to Jump to the Detailed RPD Information of This Drug | |||||||||||||||||||||||||||||||||||||||||||||||||||
Molecular Interaction Atlas of This Drug
Drug Therapeutic Target (DTT) |
|
||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Drug Off-Target (DOT) |
|
||||||||||||||||||||||||||
Molecular Interaction Atlas (MIA) | |||||||||||||||||||||||||||
Molecular Expression Atlas of This Drug
ICD Disease Classification | 13 Disease of the digestive system | |||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Disease Class | ICD-11: DD91 Irritable bowel syndrome | |||||||||||||||||||||||
The Studied Tissue | Rectal colon tissue | |||||||||||||||||||||||
The Studied Disease | Irritable bowel syndrome [ICD-11:DD91.0] | |||||||||||||||||||||||
|
||||||||||||||||||||||||
Molecular Expression Atlas (MEA) | ||||||||||||||||||||||||
Drug-Drug Interaction (DDI) Information of This Drug
Coadministration of a Drug Treating the Disease Different from Chlordiazepoxide (Comorbidity)
|
Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug
References
1 | Chlordiazepoxide FDA Label | ||||
---|---|---|---|---|---|
2 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 3370). | ||||
3 | BDDCS applied to over 900 drugs | ||||
4 | Critical Evaluation of Human Oral Bioavailability for Pharmaceutical Drugs by Using Various Cheminformatics Approaches | ||||
5 | Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds | ||||
6 | Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose | ||||
7 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. | ||||
8 | Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development. Toxicol Sci. 2010 Dec; 118(2):485-500. | ||||
9 | Chun AH, Carrigan PJ, Hoffman DJ, Kershner RP, Stuart JD "Effect of antacids on absorption of clorazepate." Clin Pharmacol Ther 22 (1977): 329-35. [PMID: 19188] | ||||
10 | US Food and Drug Administration "FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines requires its strongest warning.". | ||||
11 | Cerner Multum, Inc. "Australian Product Information.". | ||||
12 | Product Information. Synercid (dalfopristin-quinupristin) Rhone-Poulenc Rorer, Collegeville, PA. | ||||
13 | Amsden GW "Macrolides versus azalides: a drug interaction update." Ann Pharmacother 29 (1995): 906-17. [PMID: 8547740] | ||||
14 | Product Information. Tykerb (lapatinib). Novartis Pharmaceuticals, East Hanover, NJ. | ||||
15 | US Food and Drug Administration "FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines requires its strongest warning.". | ||||
16 | Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7. [PMID: 3725002] | ||||
17 | Gill SS, Wright EM, Reilly CS "Pharmacokinetic interaction of propofol and fentanyl: single bolus injection study." Br J Anaesth 65 (1990): 760-5. [PMID: 2265045] | ||||
18 | Divoll M, Greenblatt DJ, Lacasse Y, Shader RI "Benzodiazepine overdosage: plasma concentrations and clinical outcome." Psychopharmacology (Berl) 73 (1981): 381-3. [PMID: 6789361] | ||||
19 | Backman JT, Olkkola KT, Ojala M, Laaksovirta H, Neuvonen PJ "Concentrations and effects of oral midazolam are greatly reduced in patients treated with carbamazepine or phenytoin." Epilepsia 37 (1996): 253-7. [PMID: 8598183] | ||||
20 | EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports.". | ||||
21 | Cerner Multum, Inc. "UK Summary of Product Characteristics.". | ||||
22 | Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):. | ||||
23 | Abernethy DR, Greenblatt DJ, Divoll M, Moschitto LJ, Harmatz JS, Shader RI "Interaction of cimetidine with the triazolobenzodiazepines alprazolam and triazolam." Psychopharmacology (Berl) 80 (1983): 275-8. [PMID: 6137021] | ||||
24 | Product Information. Alphagan (brimonidine ophthalmic). Allergan Inc, Irvine, CA. | ||||
25 | Ochs HR, Greenblatt DJ, Knuchel M "Differential effect of isoniazid on triazolam oxidation and oxazepam conjugation." Br J Clin Pharmacol 16 (1983): 743-6. [PMID: 6140941] | ||||
26 | Ochs HR, Greenblatt DJ, Roberts GM, Dengler HJ "Diazepam interaction with antituberculosis drugs." Clin Pharmacol Ther 29 (1981): 671-8. [PMID: 7214796] | ||||
27 | Product Information. Agenerase (amprenavir). Glaxo Wellcome, Research Triangle Pk, NC. | ||||
28 | Greenblatt DJ, vonMoltke LL, Harmatz JS, Durol ALB, Daily JP, Graf JA, Mertzanis P, Hoffman JL, Shader RI "Alprazolam-ritonavir interaction: Implications for product labeling." Clin Pharmacol Ther 67 (2000): 335-41. [PMID: 10801241] | ||||
29 | Abernethy DR, Greenblatt DJ, Ameer B, Shader RI "Probenecid impairment of acetaminophen and lorazepam clearance: direct inhibition of ether glucuronide formation." J Pharmacol Exp Ther 234 (1985): 345-9. [PMID: 4020675] | ||||
30 | Blakely KM, Drucker AM, Rosen CF "Drug-induced photosensitivity-an update: Culprit drugs, prevention and management." Drug Saf 42 (2019): 827-47. [PMID: 30888626] | ||||
31 | Product Information. Zulresso (brexanolone). Sage Therapeutics, Inc., Cambridge, MA. | ||||
32 | Product Information. Reyvow (lasmiditan). Lilly, Eli and Company, Indianapolis, IN. | ||||
33 | Product Information. Addyi (flibanserin). Sprout Pharmaceuticals, Raleigh, NC. | ||||
34 | Product Information. Thalomid (thalidomide). Celgene Corporation, Warren, NJ. | ||||
35 | Product Information. Tasigna (nilotinib). Novartis Pharmaceuticals, East Hanover, NJ. | ||||
36 | Product Information. Gleevec (imatinib mesylate). Novartis Pharmaceuticals, East Hanover, NJ. | ||||
37 | Doherty MM, Charman WN "The mucosa of the small intestine: how clinically relevant as an organ of drug metabolism?" Clin Pharmacokinet 41 (2002): 235-53. [PMID: 11978143] | ||||
38 | Product Information. Gattex (teduglutide). NPS Pharmaceuticals, Bedminster, NJ. | ||||
39 | Hansen BS, Dam M, Brandt J, et al "Influence of dextropropoxyphene on steady state serum levels and protein binding of three anti-epileptic drugs in man." Acta Neurol Scand 61 (1980): 357-67. [PMID: 6998251] | ||||
40 | Sekar M, Mimpriss TJ "Buprenorphine, benzodiazepines and prolonged respiratory depression." Anaesthesia 42 (1987): 567-8. [PMID: 3592200] | ||||
41 | Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ. | ||||
42 | Product Information. Fycompa (perampanel). Eisai Inc, Teaneck, NJ. | ||||
43 | Product Information. Prograf (tacrolimus). Fujisawa, Deerfield, IL. | ||||
44 | Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA. | ||||
45 | Product Information. Zanaflex (tizanidine). Acorda Therapeutics, Hawthorne, NY. | ||||
46 | Kerin NZ, Aragon E, Faitel K, Frumin H, Rubenfire M "Long-term efficacy and toxicity of high- and low-dose amiodarone regimens." J Clin Pharmacol 29 (1989): 418-23. [PMID: 2661600] | ||||